论文部分内容阅读
[目的]观察高强度超声聚焦热疗序贯FOLFOX-4方案治疗胃癌腹膜后淋巴结转移与单纯FOLFOX-4方案治疗的疗效及安全性。[方法]85例胃癌腹膜后淋巴结转移患者随机分成两组,即高强度超声聚焦热疗序贯FOLFOX-4方案组(试验组,n=44)和单纯FOLFOX-4方案组(对照组,n=41),观察两组的治疗疗效和不良反应。[结果]最终两组的病例为44例和40例(对照组有1例患者死亡)。试验组的治疗有效率为68.2%,对照组为45.0%,两组差异具有统计学意义(P<0.05)。两组患者治疗后的疼痛和生活质量得到不同程度的改善,且试验组的改善程度均高于对照组(P<0.05)。试验组和对照组的不良反应发生率没有明显差异(P>0.05)。两组1年生存率没有明显差异(P>0.05)。[结论]高强度超声聚焦热疗序贯FOLFOX-4方案化疗治疗胃癌腹膜后淋巴结转移较单纯FOLFOX-4方案更加有效。
[Objective] To observe the curative effect and safety of high-intensity ultrasound focused thermal therapy sequential FOLFOX-4 regimen in treatment of gastric cancer with retroperitoneal lymph node metastasis and simple FOLFOX-4 regimen. [Method] Eighty-five patients with retroperitoneal lymph node metastasis of gastric cancer were randomly divided into two groups: high-intensity ultrasound focused hyperthermia sequential FOLFOX-4 regimen group (n = 44) and simple FOLFOX-4 regimen group = 41), to observe the two groups of treatment efficacy and adverse reactions. [Results] The final two groups of 44 cases and 40 cases (control group, 1 patient died). The experimental group was 68.2% effective rate, 45.0% in the control group, the difference between the two groups was statistically significant (P <0.05). After treatment, pain and quality of life in both groups improved to some extent, and the improvement in the experimental group was higher than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the experimental group and the control group (P> 0.05). There was no significant difference in one-year survival rate between the two groups (P> 0.05). [Conclusion] High-intensity ultrasound focused hyperthermia sequential FOLFOX-4 regimen is more effective in treating retroperitoneal lymph node metastasis of gastric cancer than FOLFOX-4 alone.